Limit this search to....

Considering the Patient in Pediatric Drug Development: How Good Intentions Turned Into Harm
Contributor(s): Rose, Klaus (Author)
ISBN: 0128238887     ISBN-13: 9780128238882
Publisher: Academic Press
OUR PRICE:   $148.50  
Product Type: Paperback
Published: November 2020
Qty:
Additional Information
BISAC Categories:
- Business & Economics | Industries - Pharmaceutical & Biotechnology
- Medical | Pharmacology
- Medical | Research
Dewey: 615.190
LCCN: 2020949186
Physical Information: 0.85" H x 6" W x 9" (1.22 lbs) 414 pages
 
Descriptions, Reviews, Etc.
Publisher Description:

Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm addresses a fundamental challenge in drug development and healthcare for young patients. In clinical trials and clinical practice, the term children is used ambiguously to confer physiological characteristics to a chronological age limit, which in reality does not exist. This book outlines why the United States (US) and European Union's (EU) regulatory authorities, pediatric academia, and the pharmaceutical industry demand, support and perform pediatric drug studies, along with the key flaws of this demand that blurs the different administrative and physiological meanings of the term child.

In addition, the book covers why most pediatric regulatory studies lack medical sense and many even harm young patients and the conflicts of interest behind pediatric drug studies. It includes relevant information about the maturation of the human body regarding absorption, distribution, metabolism and excretion of food and drugs as well as key differences between newborns, infants, older children and adolescents.